BH3 mimetics in cancer therapy and their future perspectives with nanodelivery

Nanomedicine (Lond). 2021 Jun;16(13):1067-1070. doi: 10.2217/nnm-2021-0059. Epub 2021 Apr 27.

Authors

Neha Mehrotra¹, Surender Kharbanda², Harpal Singh¹

Affiliations

¹ Centre for Biomedical Engineering, Indian Institute of Technology Delhi & All Indian Institute of Medical Sciences, New Delhi, Delhi 110016, India.
² Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

PMID: 33904325
DOI: 10.2217/nnm-2021-0059

No abstract available

Keywords: BH3 mimetics; cancer therapy; combination therapy; nano-delivery systems; venetoclax.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Apoptosis
Humans
Myeloid Cell Leukemia Sequence 1 Protein
Neoplasms* / drug therapy
Proto-Oncogene Proteins c-bcl-2

Substances

Antineoplastic Agents
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2